Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Meagan P O'BrienEduardo Forleo-NetoBret J MusserFlonza IsaKuo-Chen ChanNeena SarkarKatharine J BarRuanne V BarnabasDan H BarouchMyron S CohenChristopher B HurtDale R BurwenMary A MarovichPeijie HouIngeborg HeirmanJohn D DavisKenneth C TurnerDivya RameshAdnan MahmoodAndrea T HooperJennifer D HamiltonYunji KimLisa A PurcellAlina BaumChristos A KyratsousJames KrainsonRichard Perez-PerezRizwana MohseniBari KowalA Thomas DiCioccioNeil StahlLeah LipsichNed BraunsteinGary HermanGeorge D YancopoulosDavid M Weinreichnull nullPublished in: The New England journal of medicine (2021)
Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04452318.).